LPL Financial’s TScan Therapeutics TCRX Stock Holding History

LPL Financial’s Portfolio TCRX Stock Details TCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-22,500	Closed	-$22.7K	–	6348
2026 Q1	$22.7K	Hold	22,500	–	–	﹤0.01%	5864
2025 Q4	$22.5K	Buy	22,500 +1,000	+5%	+$1.45K	﹤0.01%	5801
2025 Q3	$39.1K	Buy	+21,500	New	+$38.1K	﹤0.01%	5663
2023 Q2	–	Sell	-12,000	Closed	-$25.2K	–	4681
2023 Q1	$25.2K	Sell	12,000 -5,000	-29%	-$11.9K	﹤0.01%	4387
2022 Q4	$26.4K	Buy	17,000 +2,000	+13%	+$4.91K	﹤0.01%	4339
2022 Q3	$46K	Sell	15,000 -1,000	-6%	-$3.28K	﹤0.01%	4242
2022 Q2	$50K	Buy	+16,000	New	+$43.8K	﹤0.01%	4235
2022 Q1	–	Sell	-13,000	Closed	-$59K	–	4384
2021 Q4	$59K	Buy	+13,000	New	+$93.9K	﹤0.01%	4214

Other funds holding TCRX

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

DMC

Deer Management Company Larchmont, New York $812M AUM 2.64% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

LPL Financial's TCRX Position: Q2 2026 in Review

LPL Financial sold out of TScan Therapeutics (TCRX) in Q2 2026, closing a stake of 22,500 shares — an estimated $22.7K sold.

LPL Financial first reported a position in TCRX in Q4 2021 and held it in 8 quarters. The position peaked at $59K in Q4 2021. 60 funds tracked by Wall St. Rank hold TCRX as of Q2 2026.

LPL Financial reported no remaining TScan Therapeutics position as of Q2 2026 after selling out during the quarter.
LPL Financial sold 22,500 TScan Therapeutics shares in Q2 2026, an estimated $22.7K.
LPL Financial first reported a position in TScan Therapeutics in Q4 2021 and held it in 8 quarters.
LPL Financial's TScan Therapeutics position peaked at $59K in Q4 2021.
60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q2 2026.

Based on LPL Financial's 13F filing for Q2 2026, filed 7 Aug 2026.